checkAd
    Deciphera Pharmaceuticals Aktie
    23,700
     
    EUR
    0,00 %
    0,000 EUR
    Letzter Kurs 10.06.24 Lang & Schwarz
    23,400
     
    EUR
    542 STK
    Geldkurs 10.06.24
    24,000
     
    EUR
    542 STK
    Briefkurs 10.06.24
    ISIN: US24344T1016 · WKN: A2H48H · USA

    Neueste Nachrichten

    Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
    03.06.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 13.05.2024
    13.05.24 · wO Chartvergleich · ArcticZymes Technologies
    DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH
    02.05.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders
    29.04.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
    29.04.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
    09.04.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
    27.02.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
    06.02.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
    01.02.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    01.02.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    18.01.24 · Business Wire (engl.) · Deciphera Pharmaceuticals
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 18.01.2024
    18.01.24 · wO Chartvergleich · Cerus Corporation